<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01158157</url>
  </required_header>
  <id_info>
    <org_study_id>VA-006</org_study_id>
    <nct_id>NCT01158157</nct_id>
  </id_info>
  <brief_title>Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous(VIGIV)</brief_title>
  <official_title>Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cangene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Cangene Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to vaccinate plasma donors with ACAM2000(TM) smallpox vaccine
      for collection of plasma to be used in the manufacture of Vaccinia Immune Globulin
      Intravenous (VIGIV).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma collection</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Plasma will be collected from a sufficient number of subjects vaccinated with ACAM2000 to produce approximately 60 L of plasma needed to manufacture VIGIV which will be compared to VIGIV previously collected from subjects vaccinated with Dryvax.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>To collect safety data for the use of ACAM2000™ smallpox vaccine in plasma donors who have previously been vaccinated with smallpox vaccine</description>
  </secondary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Smallpox Vaccination</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACAM2000</intervention_name>
    <description>Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent.

          -  Age 18 - 65 years.

          -  Normal and healthy as determined by medical history, physical exam, vital signs and
             clinical laboratory tests at screening visit.

          -  Subject must meet all required subject suitability criteria that pertain to normal
             Source Plasma donors.

          -  Subject must have been previously immunized for smallpox, at ≥1 year prior to
             commencement of screening assessments for the VA-006 trial, and vaccination history
             must be confirmed by oral or written history AND the presence of a visible
             pathognomonic smallpox vaccination scar.

          -  Female subjects of childbearing potential must use at least one of the following means
             of birth control documented by a physician's letter:

               -  Surgical sterilization

               -  Hormonal (oral/injectable/implant) for at least 30 days prior to vaccination

               -  IUD inserted at least 7 days prior to vaccination.

          -  Female subjects who are not using one of the methods of birth control listed above
             must be documented as postmenopausal, which is defined as not having a menstrual
             period for longer than 12 months and having a serum FSH level ≥ 40 mIU/mL.

        Exclusion Criteria:

          -  History of severe adverse event(s) from previous participation in the VA-001 or VA-005
             trials or any other smallpox vaccination program/study.

          -  Subject, household contact, or other close/intimate contact:

               -  with eczema, history of eczema, exfoliative skin conditions, wounds, burns, or
                  other skin conditions at the Investigator's discretion.

               -  with a history of immunodeficiencies (see section 7.1.2 of the protocol).

               -  who received radiotherapy or chemotherapy, ACTH, corticosteroids, or
                  immunosuppressive drugs.

               -  with eye disease treated with topical steroids.

               -  with known or suspected disorders of immunoglobulin synthesis.

               -  with leukemia, lymphomas of any type, melanoma, or other malignant neoplasms
                  affecting the bone marrow or lymphatic systems.

               -  with a history of adverse reactions to smallpox (vaccinia) vaccine.

               -  has recently been diagnosed with cancer and who will be undergoing chemotherapy
                  or radiation therapy during the vaccination healing time.

               -  is a transplant recipient (except for corneal transplant).

               -  is pregnant, planning pregnancy or breast feeding (female subjects must have
                  negative serum pregnancy test at screening and negative urine pregnancy test
                  prior to vaccination).

          -  Household or other close/intimate contact(s) under the age of 12 months.

          -  History of allergies to latex, phenol, any of the antibiotics listed in the vaccine
             content, or any other component of ACAM2000 or its diluent

          -  Severely or morbidly obese or higher obesity classification (BMI ≥ 35).

          -  Subjects with abnormal EKG and/or cardiac Troponin levels at screening.

          -  Subjects with cancer or kidney disease (except kidney stones).

          -  Subject has 3 or more of the following risk factors:

               -  High blood pressure diagnosed by a doctor

               -  High blood cholesterol diagnosed by a doctor

               -  Diabetes or high blood sugar diagnosed by a doctor

               -  A first degree relative (for example, mother, father, brother, sister) who had a
                  heart condition before the age of 50

               -  Currently smokes cigarettes

          -  Cardiovascular disease or heart condition diagnosed by a doctor at any time in the
             past, with or without symptoms, including:

               -  Arrhythmia

               -  Syncope

               -  Previous myocardial infarction

               -  Angina

               -  Coronary artery disease

               -  Congestive heart failure

               -  Cardiomyopathy

               -  Stroke or transient ischemic attack

               -  Chest pain or shortness of breath with activity (such as walking up stairs)

               -  Other heart conditions being treated by a physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cangene Plasma Resources, Mid-Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cangene Plasma Resources, Mid-Florida</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2010</study_first_submitted>
  <study_first_submitted_qc>July 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2010</study_first_posted>
  <last_update_submitted>February 28, 2012</last_update_submitted>
  <last_update_submitted_qc>February 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccinia</mesh_term>
    <mesh_term>Smallpox</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 7, 2017</submitted>
    <returned>July 7, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

